Remus Pharmaceuticals Ltd. (REMUS) Price & Analysis

0 Followers

REMUS Stock Chart & Stats

Currently, no data available

Please return soon. This page is being updated.

REMUS FAQ

What was Remus Pharmaceuticals Ltd.’s price range in the past 12 months?

Currently, no data Available

What is Remus Pharmaceuticals Ltd.’s market cap?

Currently, no data Available

When is Remus Pharmaceuticals Ltd.’s upcoming earnings report date?

Remus Pharmaceuticals Ltd.’s upcoming earnings report date is Oct 15, 2026 which is in 47 days.

How were Remus Pharmaceuticals Ltd.’s earnings last quarter?

Remus Pharmaceuticals Ltd. released its earnings results on May 20, 2026. The company reported ₹20.86 earnings per share for the quarter, beating the consensus estimate of N/A by ₹20.86.

Is Remus Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Remus Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Remus Pharmaceuticals Ltd. pay dividends?

Remus Pharmaceuticals Ltd. pays a Semiannually dividend of ₹0.5 which represents an annual dividend yield of 0.11%. See more information on Remus Pharmaceuticals Ltd. dividends here

What is Remus Pharmaceuticals Ltd.’s EPS estimate?

Remus Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Remus Pharmaceuticals Ltd. have?

Remus Pharmaceuticals Ltd. has 11,784,000 shares outstanding.

What happened to Remus Pharmaceuticals Ltd.’s price movement after its last earnings report?

Remus Pharmaceuticals Ltd. reported an EPS of ₹20.86 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Remus Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:REMUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Remus Pharmaceuticals Ltd.

Remus Pharmaceuticals Ltd. is a pharmaceutical company engaged in the marketing, trading, and distribution of finished dosage formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company's diverse product portfolio, exceeding 600 offerings, includes tablets, capsules, injections, creams, gels, eye drops, and various other dosage forms. Remus Pharmaceuticals focuses on therapeutic categories such as Critical Care, Oncology, Nephrology, Central Nervous System, Cardiology, Diabetics, Antibiotics, Immunosuppressants, Anti-inflammatory, Antifungal, Antipsychotic, Antiretroviral, Dermatology, Urology, and products for vitamin deficiency. The company primarily targets export markets, with significant operations in the Middle East, Africa, Southeast Asia, Latin America, and other emerging global markets. Leveraging an asset-light business model, Remus Pharmaceuticals collaborates with third-party and contract manufacturers, while also possessing manufacturing capabilities in India and the USA, to produce and distribute cost-effective generic alternatives. Additionally, the company provides technical and consultancy services for preparing product dossiers for international registration and engages in research and development for generic drugs and clinical trials.